SalC presents potential as a therapeutic agent, providing robust anti-inflammatory and antioxidant effects against AKI, mediated by the inhibition of signaling axes involving TLR-4, NF-κB, MAPK, HO-1, and Nrf2. The gene discussed is NFKB1; the disease is acute kidney injury.